Amara Larpthaveesarp1, Margaret Georgevits1, Donna M Ferriero2, Fernando F Gonzalez3. 1. Department of Pediatrics, University of California San Francisco, San Francisco, CA 94143, United States. 2. Department of Pediatrics, University of California San Francisco, San Francisco, CA 94143, United States; Department of Neurology, University of California San Francisco, San Francisco, CA 94143, United States. 3. Department of Pediatrics, University of California San Francisco, San Francisco, CA 94143, United States. Electronic address: Fernando.Gonzalez@ucsf.edu.
Abstract
BACKGROUND AND PURPOSE: Stroke is a major cause of neonatal morbidity, often with delayed diagnosis and with no accepted therapeutic options. The purpose of this study is to investigate the efficacy of delayed initiation of multiple dose erythropoietin (EPO) therapy in improving histological and behavioral outcomes after early transient ischemic stroke. METHODS: 32 postnatal day 10 (P10) Sprague-Dawley rats underwent sham surgery or transient middle cerebral artery occlusion (tMCAO) for 3h, resulting in injury involving the striatum and parieto-temporal cortex. EPO (1000U/kg per dose×3 doses) or vehicle was administered intraperitoneally starting one week after tMCAO (at P17, P20, and P23). At four weeks after tMCAO, sensorimotor function was assessed in these four groups (6 vehicle-sham, 6 EPO-sham, 10 vehicle-tMCAO and 10 EPO-tMCAO) with forepaw preference in cylinder rearing trials. Brains were then harvested for hemispheric volume and Western blot analysis. RESULTS: EPO-tMCAO animals had significant improvement in forepaw symmetry in cylinder rearing trials compared to vehicle-tMCAO animals, and did not differ from sham animals. There was also significant preservation of hemispheric brain volume in EPO-tMCAO compared to vehicle-tMCAO animals. No differences in ongoing cell death at P17 or P24 were noted by spectrin cleavage in either EPO-tMCAO or vehicle-tMCAO groups. CONCLUSIONS: These results suggest that delayed EPO therapy improves both behavioral and histological outcomes at one month following transient neonatal stroke, and may provide a late treatment alternative for early brain injury.
BACKGROUND AND PURPOSE:Stroke is a major cause of neonatal morbidity, often with delayed diagnosis and with no accepted therapeutic options. The purpose of this study is to investigate the efficacy of delayed initiation of multiple dose erythropoietin (EPO) therapy in improving histological and behavioral outcomes after early transient ischemic stroke. METHODS: 32 postnatal day 10 (P10) Sprague-Dawley rats underwent sham surgery or transient middle cerebral artery occlusion (tMCAO) for 3h, resulting in injury involving the striatum and parieto-temporal cortex. EPO (1000U/kg per dose×3 doses) or vehicle was administered intraperitoneally starting one week after tMCAO (at P17, P20, and P23). At four weeks after tMCAO, sensorimotor function was assessed in these four groups (6 vehicle-sham, 6 EPO-sham, 10 vehicle-tMCAO and 10 EPO-tMCAO) with forepaw preference in cylinder rearing trials. Brains were then harvested for hemispheric volume and Western blot analysis. RESULTS:EPO-tMCAO animals had significant improvement in forepaw symmetry in cylinder rearing trials compared to vehicle-tMCAO animals, and did not differ from sham animals. There was also significant preservation of hemispheric brain volume in EPO-tMCAO compared to vehicle-tMCAO animals. No differences in ongoing cell death at P17 or P24 were noted by spectrin cleavage in either EPO-tMCAO or vehicle-tMCAO groups. CONCLUSIONS: These results suggest that delayed EPO therapy improves both behavioral and histological outcomes at one month following transient neonatal stroke, and may provide a late treatment alternative for early brain injury.
Authors: Masanori Iwai; R Anne Stetler; Juan Xing; Xiaoming Hu; Yanqin Gao; Wenting Zhang; Jun Chen; Guodong Cao Journal: Stroke Date: 2010-04-01 Impact factor: 7.914
Authors: Elizabeth E Rogers; Sonia L Bonifacio; Hannah C Glass; Sandra E Juul; Taeun Chang; Dennis E Mayock; David J Durand; Dongli Song; Anthony J Barkovich; Roberta A Ballard; Yvonne W Wu Journal: Pediatr Neurol Date: 2014-08-27 Impact factor: 3.372
Authors: Cindy T J van Velthoven; R Ann Sheldon; Annemieke Kavelaars; Nikita Derugin; Zinaida S Vexler; Hanneke L D M Willemen; Mirjam Maas; Cobi J Heijnen; Donna M Ferriero Journal: Stroke Date: 2013-03-28 Impact factor: 7.914
Authors: Niek E van der Aa; Jeroen Dudink; Manon J N L Benders; Paul Govaert; Henrica L M van Straaten; Giorgio L Porro; Floris Groenendaal; Linda S de Vries Journal: Dev Med Child Neurol Date: 2013-01-22 Impact factor: 5.449
Authors: C Manabat; B H Han; M Wendland; N Derugin; C K Fox; J Choi; D M Holtzman; D M Ferriero; Z S Vexler Journal: Stroke Date: 2003-01 Impact factor: 7.914
Authors: Sandra E Juul; Bryan A Comstock; Patrick J Heagerty; Dennis E Mayock; Amy M Goodman; Stephanie Hauge; Fernando Gonzalez; Yvonne W Wu Journal: Neonatology Date: 2018-03-07 Impact factor: 4.035
Authors: R Ann Sheldon; Christine Windsor; Byong Sop Lee; Olatz Arteaga Cabeza; Donna M Ferriero Journal: Dev Neurosci Date: 2017-04-27 Impact factor: 2.984
Authors: Nienke Wagenaar; Caroline G M de Theije; Linda S de Vries; Floris Groenendaal; Manon J N L Benders; Cora H A Nijboer Journal: Pediatr Res Date: 2017-11-01 Impact factor: 3.756
Authors: Amara Larpthaveesarp; Praneeti Pathipati; Samuel Ostrin; Anthony Rajah; Donna Ferriero; Fernando F Gonzalez Journal: Stroke Date: 2020-12-22 Impact factor: 7.914